What is the long-term trend for CareDx's indefinite-lived research and development assets?

Over 2 years (2023 to 2025), CareDx's indefinite-lived research and development assets has grown at a -6.3% compound annual growth rate (CAGR), from $3.98M to $3.49M.

CareDx CDNA Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

AbbottABT

$1.2B+53.1%

Other financials

Income statement

See full

Revenue$117.7M+39.0%

Operating income$1.2M+109%

Net income$2.8M+127%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$78.5M-12.1%

Total debt$24.5M-19.1%

Total equity$313.5M-17.3%

Total assets$411.1M-16.0%

Cash flow

See full

Operating cash flow$4.3M+116%

CapEx$3.8M+134%

Free cash flow$514.0K+102%

Valuation

See full

Market cap$1.4B+32.2%

Enterprise value$1.35B+34.6%

P/S3.4×+0.3×

Profitability

See full

Gross margin65.5%—

Operating margin-3.9%-18.3pp

Net margin-2%-19.9pp

FCF margin-0%0.0pp

Returns & leverage

See full

Return on equity-2.4%-21.9pp

Debt / equity0.1×0.0×

Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CareDx's indefinite-lived research and development assets?: CareDx (CDNA) reported indefinite-lived research and development assets of $3.49M in Q1 2026.
How has CareDx's indefinite-lived research and development assets changed year-over-year?: CareDx's indefinite-lived research and development assets decreased by 0.0% year-over-year, from $3.49M to $3.49M.
What is the long-term trend for CareDx's indefinite-lived research and development assets?: Over 2 years (2023 to 2025), CareDx's indefinite-lived research and development assets has grown at a -6.3% compound annual growth rate (CAGR), from $3.98M to $3.49M.